Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bone Biologics Corp Warrants (BBLGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: BBLGW (1-star) is a SELL. SELL since 3 days. Profits (-79.95%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.83% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.28 | 52 Weeks Range 3.00 - 95.04 | Updated Date 06/28/2025 |
52 Weeks Range 3.00 - 95.04 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.73% | Return on Equity (TTM) -129.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 537318 |
Shares Outstanding - | Shares Floating 537318 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Bone Biologics Corp Warrants
Company Overview
History and Background
Bone Biologics Corp (BBLG) is a development-stage biotechnology company. Information on the warrants is limited, but warrants are often issued in conjunction with an offering of stock or other securities, representing the right to purchase additional shares at a specified price within a specific timeframe.
Core Business Areas
- Orthobiologics: Bone Biologics is focused on orthobiologics, specifically developing products for bone regeneration.
Leadership and Structure
Information on Bone Biologics Corp's leadership and organizational structure is limited. Refer to the company's website or SEC filings for detailed information.
Top Products and Market Share
Key Offerings
- NBG-002: NBG-002 is Bone Biologics' lead product candidate, a bone graft substitute intended to promote bone regeneration. Market share data is not readily available. Competitors include Medtronic, Johnson & Johnson, and Stryker in the bone graft market.
Market Dynamics
Industry Overview
The orthobiologics market is growing due to the aging population, increasing demand for minimally invasive procedures, and advancements in regenerative medicine.
Positioning
Bone Biologics is a small player in a competitive orthobiologics market. Its success depends on the clinical and commercial viability of NBG-002.
Total Addressable Market (TAM)
The global orthobiologics market is estimated in the billions of dollars. Bone Biologics' TAM depends on the specific indications NBG-002 targets and its market penetration. Given its development stage, their current positioning represents a very small fraction of the total available market.
Upturn SWOT Analysis
Strengths
- Novel technology (NBG-002)
- Potential for bone regeneration
- Focus on a growing market
Weaknesses
- Limited financial resources
- Development-stage company
- Dependence on NBG-002 success
- Small market capitalization
Opportunities
- Partnerships with larger companies
- Expansion into new indications
- Positive clinical trial results
- FDA approval of NBG-002
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
- Funding challenges
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- SYK
Competitive Landscape
Bone Biologics faces intense competition from larger, well-established companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to development stage.
Future Projections: Future growth depends on NBG-002's clinical and commercial success.
Recent Initiatives: Focus on clinical development and potential partnerships.
Summary
Bone Biologics is a high-risk, high-reward development-stage company. Its future depends heavily on the success of NBG-002. The warrants represent an opportunity to participate in potential upside, but also carry significant risk due to the company's financial situation and development stage. Success depends on the company's ability to navigate regulatory hurdles and secure adequate funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and based on available data, which may be limited.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bone Biologics Corp Warrants
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2021-10-13 | CEO & President Mr. Jeffrey Frelick | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2 | Website https://www.bonebiologics.com |
Full time employees 2 | Website https://www.bonebiologics.com | ||
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.